Why Supernus Pharmaceuticals (SUPN) Shares Are Trading Lower Today

What Happened?

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 16.8% in the morning session after the company's third-quarter 2025 earnings report, as a weak full-year forecast overshadowed beats on revenue and earnings per share (EPS). 

The specialty pharmaceutical company posted revenue of $192.1 million, up 9.3% from the prior year and ahead of Wall Street's expectations. Its GAAP earnings of $0.80 per share also significantly topped analysts' consensus estimates. However, investor enthusiasm was dampened by the company's full-year revenue guidance, which, at a midpoint of $695 million, came in slightly below analyst forecasts. Additionally, the company's operating margin contracted significantly compared to the same quarter last year, contributing to the negative market reaction. The results suggest that while the quarter was strong, concerns about the company's future growth trajectory weighed on investor sentiment.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Supernus Pharmaceuticals? Access our full analysis report here.

What Is The Market Telling Us

Supernus Pharmaceuticals’s shares are not very volatile and have only had 5 moves greater than 5% over the last year. Moves this big are rare for Supernus Pharmaceuticals and indicate this news significantly impacted the market’s perception of the business.

The previous big move we wrote about was 27 days ago when the stock gained 4.6% on the news that Piper Sandler upgraded the company's stock from a "Neutral" to an "Overweight" rating and raised its price target. The investment firm increased its price target on the shares to $65 from a previous target of $40. The upgrade was influenced by the promising potential of Onapgo, Supernus's recently launched continuous subcutaneous infusion pump designed for advanced Parkinson's disease. Analysts noted the product's potential to expand profit margins and grow earnings before interest, taxes, depreciation, and amortization (EBITDA), a measure of a company's overall financial performance.

Supernus Pharmaceuticals is up 27.4% since the beginning of the year, but at $46.43 per share, it is still trading 18.6% below its 52-week high of $57 from November 2025. Investors who bought $1,000 worth of Supernus Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $2,016.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.